X4 Pharmaceuticals, Inc.XFORNASDAQ
LOADING
|||
EPS Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year earnings per share growth rate
Latest
80.12%
↑ 167% above average
Average (36q)
-119.53%
Historical baseline
Range
High:5330.77%
Low:-8997.44%
Volatility
-11986.6%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | 80.12% |
| Q2 2025 | -8997.44% |
| Q1 2025 | 100.65% |
| Q4 2024 | -11.11% |
| Q3 2024 | -101.32% |
| Q2 2024 | 5330.77% |
| Q1 2024 | -170.27% |
| Q4 2023 | -722.22% |
| Q3 2023 | 96.45% |
| Q2 2023 | -106.25% |
| Q1 2023 | 44.83% |
| Q4 2022 | -11.54% |
| Q3 2022 | 56.67% |
| Q2 2022 | 16.67% |
| Q1 2022 | 41.94% |
| Q4 2021 | -63.16% |
| Q3 2021 | -2.70% |
| Q2 2021 | 43.08% |
| Q1 2021 | -42.86% |
| Q4 2020 | -4.60% |
| Q3 2020 | -14.47% |
| Q2 2020 | -35.71% |
| Q1 2020 | 15.15% |
| Q4 2019 | 45.90% |
| Q3 2019 | -19.61% |
| Q2 2019 | 39.47% |
| Q1 2019 | 93.58% |
| Q4 2018 | -28.64% |
| Q3 2018 | -37.49% |
| Q2 2018 | 16.21% |
| Q1 2018 | -8.87% |
| Q4 2017 | 44.43% |
| Q3 2017 | -103.15% |
| Q2 2017 | -6.05% |
| Q1 2017 | -1.22% |
| Q4 2016 | 0.00% |
| Q1 2016 | 0.00% |